FDA Adds a Vision Warning to Zepbound Days After Lilly’s November 6 Hims & Hers Deal
Eli Lilly (LLY) and Hims & Hers (HIMS) partnered to sell Zepbound and Foundayo directly on Hims' platform. Lilly's Q3 revenue rose 39% to $24.4B, with volume up 53% and prices down 15%. The FDA added a vision warning to GLP-1 drugs, including Lilly's products. Novo Nordisk (NVO) also sells GLP-1 drugs on Hims.
How this was made
The 30-second read
Why it matters
The regulatory warning introduces a risk factor for Lilly's GLP‑1 portfolio, but the partnership with Hims may drive volume and margin expansion.
Market read
New FDA warning creates short‑term downside risk for Lilly, while the Hims partnership offers a growth catalyst; investors must weigh both.
What to watch
Volume growth of 53% and improved gross margin could offset the warning's negative sentiment.
Background
Eli Lilly expands its direct‑to‑consumer sales on Hims & Hers while the FDA issues a new vision warning for all GLP‑1 drugs, including Zepbound.
Ticker impact
The FDA added a vision warning to Zepbound, a GLP‑1 sold by Eli Lilly, marking a new regulatory action affecting the drug.
likely pressure as the market prices in the safety caveat
The warning is a fresh FDA action; investors typically react negatively to new safety labels on high‑growth drugs.
Eli Lilly now sells Zepbound and Foundayo directly on the Hims & Hers platform, expanding its sales channel.
potential upside as the partnership may increase revenue
The deal adds a new sales avenue for Hims, but the impact depends on patient adoption.
Market effects
GLP‑1 market faces heightened regulatory scrutiny, which could affect peers.
U.S. biotech sector may see modest pullback amid the warning.
International GLP‑1 manufacturers watch the FDA action for precedent.
Counterpoint
The warning may be a minor label change with limited sales impact, allowing the stock to stay resilient.
Key entities
- companyEli Lilly
Pharmaceutical maker of GLP‑1 drugs Zepbound and Foundayo.
- companyHims & Hers Health
Telehealth platform now selling Lilly's GLP‑1 products directly.
- regulatorFDA
U.S. Food and Drug Administration adding a vision warning to GLP‑1 labels.
